deltatrials
Terminated PHASE2 NCT00003454

Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Breast

Sponsor: Burzynski Research Institute

Conditions Stage IV Breast Cancer
Interventions Antineoplaston therapy (Atengenal + Astugenal)
Updated 6 times since 2017 Last updated: Sep 26, 2017 Started: Mar 18, 1996 Primary completion: Dec 28, 2002 Completion: Dec 28, 2002

A PHASE2 clinical study on Stage IV Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Burzynski Research Institute and has accumulated 6 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

▶ Show 1 earlier version

  1. Jan 2017 — Oct 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Mar 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Burzynski Research Institute
Data source: Burzynski Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States